Janssen (Johnson & Johnson) Deal History & Licensing Activity
Janssen (Johnson & Johnson) is a large pharma headquartered in US. Over the past three years, Janssen (Johnson & Johnson) has been involved in 8 licensing and acquisition transactions, with a primary focus on Small Molecules (9 deals). The company currently has 2 active clinical trials, primarily in Codev Deals.
Deals (12mo)
6
Active Trials
2
Top Modality
Small Molecules
Focus Area
Codev Deals
Janssen (Johnson & Johnson) Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Janssen (Johnson & Johnson) in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Imbruvica | Janssen | Small Molecules | Approved | co development | Jul 20, 2026 |
| Imbruvica | AbbVie | Small Molecules | Approved | co development | Jul 18, 2026 |
| Imbruvica | Janssen | Small Molecules | Approved | co development |
Janssen (Johnson & Johnson) Pipeline Focus
Therapeutic areas and modalities where Janssen (Johnson & Johnson) is most active based on deal history and clinical trial data.
Therapeutic Areas
Janssen (Johnson & Johnson) Strategic Signals
Key indicators of Janssen (Johnson & Johnson)'s licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Janssen (Johnson & Johnson) Clinical Pipeline
Janssen (Johnson & Johnson) has 2 active clinical trials across 2 development phases.
1
Not Applicable
1
Phase 4
See How Your Asset Matches Janssen (Johnson & Johnson)'s Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Codev Deals assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
ADC Benchmarks
Upfront, milestone, and royalty benchmarks for adc deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Janssen (Johnson & Johnson) Licensing & Deal Activity
Janssen (Johnson & Johnson) is a large pharma company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 8 deals over the past three years, Janssen (Johnson & Johnson) ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Janssen (Johnson & Johnson) include Codev Deals (6 deals and trials), Oncology (4 deals and trials), Other (2 deals and trials), and Infectious Disease (2 deals and trials). In terms of modality, Janssen (Johnson & Johnson) has shown particular interest in small molecules, adc, oligonucleotides.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Janssen (Johnson & Johnson) and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Janssen (Johnson & Johnson)'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.